Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Estradiol Cypionate

FDA-approved product (injectable, injection), marketed as Depo-Estradiol, Estradiol Cypionate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Estradiol Cypionate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atrophic Vaginitis
  • Atrophy
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Dyspareunia
  • Hypogonadism
  • Menopause
  • Osteoporosis
  • Postmenopausal atrophic vaginitis
  • Postmenopausal osteoporosis
  • Premature ovarian insufficiency
  • Primary ovarian insufficiency

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Natural and semisynthetic estrogens, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Estradiol Cypionate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-10.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Estradiol Cypionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clinical Efficacy of Hormone Replacement Therapy in Treating Perimenopausal Women With MGD

    NCT04962386 · start 2019-03-06

    Registered record
    Registry ID
    NCT04962386
    Conditions
    Meibomian Gland Dysfunction
    Interventions
    Hormone replacement therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-03-06
    Completion
    2022-03-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeibomian Gland Dysfunction
    InterventionHormone replacement therapy
    PhaseNot recorded
    Registry statusUnknown

  • A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

    NCT03584009 · start 2018-09-06

    Registered record
    Registry ID
    NCT03584009
    Conditions
    Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
    Interventions
    Venetoclax; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-09-06
    Completion
    2021-05-06
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
    InterventionVenetoclax; Fulvestrant
    PhasePhase 2
    Registry statusTerminated

  • Estrogen and the Urogenital Microbiome in GSM

    NCT03336437 · start 2018-02-01

    Registered record
    Registry ID
    NCT03336437
    Conditions
    Menopause
    Interventions
    Estradiol vaginal ring; Placebo vaginal ring
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-02-01
    Completion
    2019-08-23
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause
    InterventionEstradiol vaginal ring; Placebo vaginal ring
    PhasePhase 4
    Registry statusCompleted

  • SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

    NCT03204318 · start 2017-12-07

    Registered record
    Registry ID
    NCT03204318
    Conditions
    Endometriosis Related Pain
    Interventions
    Relugolix; Estradiol/norethindrone acetate; Estradiol/norethindrone acetate placebo; Relugolix placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-12-07
    Completion
    2021-04-08
    Enrolment
    638

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis Related Pain
    InterventionRelugolix; Estradiol/norethindrone acetate; Estradiol/norethindrone acetate placebo; Relugolix placebo
    PhasePhase 3
    Registry statusCompleted

  • Early Preparation With Gonadotropin- Releasing Hormon (GnRh) Agonists Injection With Frozen-Thawed Embryo Transfer?

    NCT03353883 · start 2017-06-01

    Registered record
    Registry ID
    NCT03353883
    Conditions
    Infertility, Female
    Interventions
    Triptorelin SR
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2017-06-01
    Completion
    2018-08
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility, Female
    InterventionTriptorelin SR
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

    NCT02763566 · start 2016-12-05

    Registered record
    Registry ID
    NCT02763566
    Conditions
    Breast Cancer
    Interventions
    Abemaciclib; Anastrozole; Letrozole; Placebo; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2016-12-05
    Completion
    2028-03
    Enrolment
    463

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionAbemaciclib; Anastrozole; Letrozole; Placebo +1 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Menopause Effects on Vascular Function

    NCT03236545 · start 2016-07-01

    Registered record
    Registry ID
    NCT03236545
    Conditions
    Cardiovascular Risk Factor
    Interventions
    No to Low Endogenous Estrogen; Estradiol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-07-01
    Completion
    2022-11-01
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Risk Factor
    InterventionNo to Low Endogenous Estrogen; Estradiol
    PhaseNot applicable
    Registry statusCompleted

  • A Study Comparing Estradiol Vaginal Cream to Estrace® Cream in Females With Atrophic Vaginitis

    NCT02995694 · start 2016-03

    Registered record
    Registry ID
    NCT02995694
    Conditions
    Atrophic Vaginitis
    Interventions
    Estradiol; Placebos; Reference
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-03
    Completion
    2016-12
    Enrolment
    535

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrophic Vaginitis
    InterventionEstradiol; Placebos; Reference
    PhasePhase 3
    Registry statusCompleted

  • Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase

    NCT02640755 · start 2016-01-28

    Registered record
    Registry ID
    NCT02640755
    Conditions
    Solid Malignancies
    Interventions
    [14C]AZD2014; Multiple dose AZD2014; Fulvestrant; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-01-28
    Completion
    2017-07-06
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Malignancies
    Intervention[14C]AZD2014; Multiple dose AZD2014; Fulvestrant; Paclitaxel
    PhasePhase 1
    Registry statusCompleted

  • Perimenopausal Effects of Estradiol on Reward Responsiveness

    NCT02255175 · start 2015-10-01

    Registered record
    Registry ID
    NCT02255175
    Conditions
    Perimenopausal Depression
    Interventions
    Estradiol; Progesterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-10-01
    Completion
    2018-10-17
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerimenopausal Depression
    InterventionEstradiol; Progesterone
    PhasePhase 4
    Registry statusCompleted

  • Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics

    NCT02531321 · start 2015-08

    Registered record
    Registry ID
    NCT02531321
    Conditions
    Contraception; HIV
    Interventions
    Levonorgestrel and Ethinyl Estradiol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2015-08
    Completion
    2016-11-01
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception; HIV
    InterventionLevonorgestrel and Ethinyl Estradiol
    PhasePhase 4
    Registry statusTerminated

  • Drug Utilization Study on Diane-35 (and Generics) in Three European Healthcare Databases

    NCT02349399 · start 2015-05-01

    Registered record
    Registry ID
    NCT02349399
    Conditions
    Acne Vulgaris
    Interventions
    Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-05-01
    Completion
    2016-03-01
    Enrolment
    26,065

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionCyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics
    PhaseNot recorded
    Registry statusCompleted

  • Investigation of Female Reproductive Hormone Dynamics During Adolescence

    NCT02486757 · start 2015-04

    Registered record
    Registry ID
    NCT02486757
    Conditions
    Menstruation Disturbances
    Interventions
    micronized progesterone; transdermal estradiol
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2015-04
    Completion
    2016-03-01
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenstruation Disturbances
    Interventionmicronized progesterone; transdermal estradiol
    PhaseEarly phase 1
    Registry statusCompleted

  • Efficacy and Tolerability of a Nutritional Supplement, Plactive Progen, in ACL Reconstruction

    NCT03355651 · start 2015-03-09

    Registered record
    Registry ID
    NCT03355651
    Conditions
    ACL Reconstruction
    Interventions
    PROGEN
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-03-09
    Completion
    2017-03-03
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionACL Reconstruction
    InterventionPROGEN
    PhaseNot applicable
    Registry statusCompleted

  • The Effect of Oral Contraceptive Pills On Eyes

    NCT02841202 · start 2014-01

    Registered record
    Registry ID
    NCT02841202
    Conditions
    Adverse Effect of Oral Contraceptives, Subsequent Encounter
    Interventions
    oral contraceptive pills
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-01
    Completion
    2016-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdverse Effect of Oral Contraceptives, Subsequent Encounter
    Interventionoral contraceptive pills
    PhasePhase 4
    Registry statusCompleted